Eosinophilic esophagitis

Disease ID:1195
Name:Eosinophilic esophagitis
Associated with:0 targets
0 immuno-relevant targets
1 immuno-relevant ligands
An esophagitis characterized by inflammation resulting from eosinophil activity in the esophagus.
Database Links
Disease Ontology: DOID:13922
Orphanet: ORPHA73247


No target related data available for Eosinophilic esophagitis


Ligand Approved Immuno References Clinical comments
Clinical Use: Dectrekumab (QBX258) reached Phase II clinical trial as a potential biologic therapy for several immune conditions, including idiopathic pulmonary fibrosis (IPF), asthma, eosinophilic esophagitis [1] (proof of principle study NCT01022970), Crohn's disease, keloids and allergic rhinitis. As of May 2017, there are no active dectrekumab studies.
Immuno Disease Comments: Phase 2 trial NCT01022970 in eosinophilic esophagitis has been completed.


Show »

1. Rothenberg ME, Wen T, Greenberg A, Alpan O, Enav B, Hirano I, Nadeau K, Kaiser S, Peters T, Perez A et al.. (2015) Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J. Allergy Clin. Immunol., 135 (2): 500-7. [PMID:25226850]